Granulomatous hepatitis as a late complication of BCG immunotherapy
- 15 October 1980
- Vol. 46 (8) , 1759-1762
- https://doi.org/10.1002/1097-0142(19801015)46:8<1759::aid-cncr2820460810>3.0.co;2-6
Abstract
A case of BCG-induced granulomatous hepatitis, which developed 1 1/2 years after BCG immunotherapy for recurrent malignant melanoma, is described to document the development of this disease entity as a potential late complication of BCG immunotherapy. The clinical implications of the late development of BCG-induced granulomatous hepatitis, use of immunosuppressive chemotherapy, and possible alternatives for BCG in intratumor immunotherapy are discussed.This publication has 11 references indexed in Scilit:
- Intralesional injection of the methanol extraction residue of bacillus calmette-guerin (MER) into cutaneous metastases of malignant melanomaCancer, 1978
- Disseminated bcg disease associated with immunotherapy by scarification in acute leukemiaCancer, 1978
- Effect of Isonicotinic Acid Hydrazide on the Intratumor Injection of BCG2JNCI Journal of the National Cancer Institute, 1977
- Case 34-1975New England Journal of Medicine, 1975
- Complications of BCG Vaccination in Neoplastic DiseaseAnnals of Internal Medicine, 1975
- Immunotherapy of melanoma with BCG: Two fatalities following intralesional injectionCancer, 1975
- RESULTS OF ADMINISTERING B.C.G. TO PATIENTS WITH MELANOMAThe Lancet, 1974
- BCG and CancerNew England Journal of Medicine, 1974
- GRANULOMATOUS HEPATITIS: A COMPLICATION OF B.C.G. IMMUNOTHERAPYThe Lancet, 1973